BioWorld Science

May 28, 2018

View Archived Issues

Atridia begins phase I study of SHR-0410 in healthy volunteers

Read More

New phase I trial studies GD2-specific CAR and IL-15 expressing NKTs in neuroblastoma

Read More

Bionomics initiates phase II study of BNC-210 for the treatment of agitation in elderly

Read More

Discovery of novel inhibitor of human NMT for treatment of the common cold

Read More

First patient enrolled in SARA-INT study of Sarconeos in sarcopenia

Read More

Lilly initiates phase II study of LY-3303560 in early symptomatic AD

Read More

Lupin submits MAA to the EMA for etanercept biosimilar

Read More

Fluorescent imaging with a myelin-binding probe shows promise

Read More

PCI Biotech Holding, IMV enter research collaboration

Read More

Janssen Pharmaceutica patents new PDE2A inhibitors

Read More

Oncolytics Biotech and the Keck School of Medicine collaborate to study new Reolysin combination

Read More

Japanese approval for Opdivo with Yervoy in unresectable melanoma

Read More

Roche and Genentech disclose IRAK-4 inhibitors

Read More

Beactica extends master service agreement with Sanofi

Read More

Croma-Pharma identifies H2S-releasing compounds

Read More

Janssen to terminate studies of daratumumab with atezolizumab and JNJ-63723283

Read More

Pfizer's Xeljanz approved for new indication in Japan

Read More

Janssen Pharmaceutica discloses BACE1 and/or BACE2 inhibitors

Read More

Braeburn resubmits CAM-2038 NDA for opioid use disorder to FDA

Read More

Roche presents compounds for HBV infection

Read More

New phase I study evaluates MRX-2843 in patients with advanced or metastatic solid tumors

Read More

MedImmune initiates phase I study of MEDI-2228 in relapsed or refractory multiple myeloma

Read More

Symphogen opens enrollment in phase I study of Sym-023 in advanced solid tumors or lymphomas

Read More

Mepolizumab approved for EGPA in Japan

Read More

Polysialic acid levels tied to prostate cancer aggressiveness

Read More